Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAL-222
- Development stage
- Unknown
- Lead developer
- PharmaBio
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Implant
01
Overview
PAL-222 is an allogeneic cell therapy product developed by PharmaBio Corporation, consisting of mesenchymal stem cells derived from the human amniotic membrane (AM-MSCs). The product is formulated as a transplantable sheet intended for regenerative medicine applications. PAL-222 is currently undergoing Phase I/IIa clinical evaluation for the treatment of refractory skin ulcers, where it is surgically implanted into the ulcer site, and for ophthalmic conditions including neovascular age-related macular degeneration (nAMD) and myopic chorioretinal atrophy, where it is placed into the subretinal space. The therapy aims to utilize the immunomodulatory and tissue-regenerative properties of amniotic-derived stem cells to promote healing and provide trophic support in patients who have failed to respond to existing standard-of-care treatments.
- Other names
- allogeneic amniotic membrane-derived mesenchymal stem cellsAM-MSC sheet
Beyond the preview
Go deeper on PAL-222.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAL-222.